Catalent, Inc. (NYSE:CTLT) Holdings Raised by Alpine Associates Management Inc.

Alpine Associates Management Inc. raised its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,131,126 shares of the company's stock after acquiring an additional 69,875 shares during the period. Catalent makes up approximately 5.9% of Alpine Associates Management Inc.'s holdings, making the stock its 4th biggest holding. Alpine Associates Management Inc. owned 1.17% of Catalent worth $129,082,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in CTLT. Russell Investments Group Ltd. lifted its holdings in Catalent by 14.9% in the first quarter. Russell Investments Group Ltd. now owns 27,636 shares of the company's stock valued at $1,560,000 after acquiring an additional 3,578 shares during the period. Vanguard Group Inc. grew its position in Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company's stock valued at $1,151,872,000 after buying an additional 218,682 shares during the period. O Shaughnessy Asset Management LLC purchased a new position in Catalent in the first quarter valued at $214,000. UniSuper Management Pty Ltd boosted its stake in shares of Catalent by 509.4% during the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company's stock worth $1,028,000 after acquiring an additional 15,217 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in shares of Catalent by 0.9% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 89,451 shares of the company's stock valued at $5,050,000 after acquiring an additional 764 shares during the period.

Catalent Trading Up 0.0 %

CTLT stock traded up $0.02 during trading on Wednesday, reaching $58.90. 793,241 shares of the stock were exchanged, compared to its average volume of 2,023,306. The business has a 50 day moving average price of $59.80 and a 200-day moving average price of $58.25. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.20. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $10.69 billion, a price-to-earnings ratio of -26.04, a P/E/G ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted ($0.10) earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CTLT shares. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a "neutral" rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a report on Thursday, November 14th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $63.40.

Insiders Place Their Bets

In related news, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock worth $305,931 over the last 90 days. Corporate insiders own 0.31% of the company's stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.